PALOMA-1 study of palbociclib in ER+, HER2-, breast cancer
12th May 2015
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Véronique Diéras (Institut Curie, Paris, France) discusses the phase 2 PALOMA-1 study of the cyclin-dependent kinase 4/6 inhibitor, palbociclib, in combination with letrozole versus letrozole alone as first-line treatment for women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. The addition of palbociclib to letrozole significantly improved progression-free survival in this patient population. A phase 3 trial has begun.
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?
Keep your finger on the pulseJoin Now
Elevating the Quality of Healthcare Globally